Cts Corporation (NYSE:CTS) had an increase of 13.77% in short interest. CTS’s SI was 470,000 shares in June as released by FINRA. Its up 13.77% from 413,100 shares previously. With 108,000 avg volume, 4 days are for Cts Corporation (NYSE:CTS)’s short sellers to cover CTS’s short positions. The SI to Cts Corporation’s float is 1.45%. The stock increased 0.07% or $0.02 during the last trading session, reaching $33.47. About 60,494 shares traded. CTS Corporation (NYSE:CTS) has risen 54.57% since June 13, 2017 and is uptrending. It has outperformed by 42.00% the S&P500. Some Historical CTS News: ; 13/03/2018 – ADVANCED MICRO SAYS CTS LABS PREVIOUSLY UNKNOWN TO CO; 04/05/2018 – Massachusetts Financial Services Buys New 1.5% Position in CTS; 16/04/2018 – S&PGR Asgns Verus Securitization Trust 2018-INV1 Cts Prlm Rtgs; 22/03/2018 – CTS EVENTIM EVDG.DE DIVIDEND 0.59 EUR/SHR; 24/04/2018 – CME GROUP CME.O SAYS RAISES STORAGE RATES ON K.C. WHEAT FUTURES 0#KW: TO 11 CTS/BU PER MONTH UP FROM 8 CTS AFTER INITIAL VARIABLE STORAGE RATE OBSERVATION PERIOD; 17/05/2018 – CTS Corporation Declares A Dividend; 04/04/2018 – CTS Increases Size of Board, Names Alfonso G. Zulueta As Director; 13/03/2018 – CTS LABS SAYS VULNERABILITIES IT FOUND IN AMD CHIPS HAVE POTENTIAL TO PUT ORGANIZATIONS AT “SIGNIFICANTLY INCREASED RISK OF CYBER-ATTACKS”; 30/05/2018 – CTS Eventim AG & Co. KGaA: Waldbühne Berlin opens new backstage area; 22/03/2018 – DGAP-NEWS: CTS EVENTIM AG & CO. KGAA: CTS EVENTIM ACHIEVES RECORD RESULTS IN 2017, EXCEEDS ONE BILLION EURO IN REVENUES FOR THE FIRST TIME EVER
The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) hit a new 52-week low and has $4.71 target or 8.00% below today’s $5.12 share price. The 8 months bearish chart indicates high risk for the $183.70 million company. The 1-year low was reported on Jun, 13 by Barchart.com. If the $4.71 price target is reached, the company will be worth $14.70 million less. The stock increased 8.47% or $0.4 during the last trading session, reaching $5.12. About 368,228 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 65.69% since June 13, 2017 and is downtrending. It has underperformed by 78.26% the S&P500. Some Historical CALA News: ; 15/05/2018 – Viking Global Investors LP Exits Calithera Biosciences; 08/03/2018 – CALITHERA BIOSCIENCES – EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE BETWEEN $105 AND $115 MLN AT END OF 2018; 08/03/2018 – CALITHERA – EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS WILL BE SUFFICIENT TO MEET CURRENT OPERATING PLAN THROUGH 2020, EXCLUSIVE OF SOME ITEMS; 23/03/2018 – Calithera Biosciences Presenting at Conference Mar 28; 08/03/2018 – Calithera Biosciences Sees Cash, Cash Equivalents and Investments Between $105M and $115M at 2018 End; 08/03/2018 Calithera Biosciences 4Q Loss/Shr 31c; 09/05/2018 – Federated Investors Buys 4% Position in Calithera Biosciences; 08/03/2018 – Calithera Biosciences Sees Cash, Cash Equivalents and Investments Will Sufficient to Meet Operating Plan Through 2020; 18/04/2018 – Calithera Biosciences: FDA Fast Track Designation Granted to CB-839 in Combination With Cabozantini; 10/05/2018 – Calithera Biosciences 1Q Loss/Shr 37c
Among 2 analysts covering CTS Corp (NYSE:CTS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CTS Corp had 2 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, July 29 the stock rating was downgraded by Gabelli to “Hold”.
Investors sentiment decreased to 1.2 in 2018 Q1. Its down 0.23, from 1.43 in 2017Q4. It is negative, as 12 investors sold CTS Corporation shares while 37 reduced holdings. 21 funds opened positions while 38 raised stakes. 30.31 million shares or 2.39% less from 31.05 million shares in 2017Q4 were reported. Aqr Capital Management Llc reported 0% of its portfolio in CTS Corporation (NYSE:CTS). Comerica Bank & Trust has 0.01% invested in CTS Corporation (NYSE:CTS) for 34,585 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 41,951 shares. Moreover, Cardinal Capital Management Lc Ct has 0.94% invested in CTS Corporation (NYSE:CTS) for 929,117 shares. Morgan Stanley invested 0% in CTS Corporation (NYSE:CTS). Massmutual Tru Fsb Adv stated it has 0% of its portfolio in CTS Corporation (NYSE:CTS). Zacks Inv reported 0.04% in CTS Corporation (NYSE:CTS). 7,893 were reported by Millennium Mngmt Limited Com. Prudential Inc reported 0% stake. Prelude Cap Mngmt Ltd Liability Corp has invested 0% in CTS Corporation (NYSE:CTS). Thrivent Financial For Lutherans reported 21,285 shares. Deutsche National Bank Ag invested in 0% or 232,128 shares. State Board Of Administration Of Florida Retirement Systems holds 40,927 shares. Pinebridge Investments L P, a New York-based fund reported 49,440 shares. Geode Management Ltd has invested 0% in CTS Corporation (NYSE:CTS).
CTS Corporation designs, manufactures, and sells a range of sensors, electronic components, and actuators primarily to original equipment manufacturers for the transportation, industrial, medical, information technology, defense and aerospace, and communications markets. The company has market cap of $1.11 billion. It offers sensors and actuators used in passenger or consumer vehicles; electronic components used in infrastructure, information technology and other high-speed applications, switches, and potentiometers supplied to various markets; and fabricated piezoelectric materials and substrates used primarily in medical, industrial, defense and aerospace, and information technology markets. It has a 77.85 P/E ratio. The firm also creates and develops sensing technology for radio frequency measurement and control systems.
Another recent and important CTS Corporation (NYSE:CTS) news was published by Globenewswire.com which published an article titled: “CTS Corporation Declares A Dividend” on May 17, 2018.
Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was initiated by Citigroup on Tuesday, October 25 with “Sell”. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, January 5 report. H.C. Wainwright maintained Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, March 28 with “Buy” rating. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) earned “Neutral” rating by Citigroup on Tuesday, January 24. The firm has “Buy” rating by Citigroup given on Friday, July 24. H.C. Wainwright maintained Calithera Biosciences, Inc. (NASDAQ:CALA) on Monday, June 12 with “Buy” rating. Citigroup upgraded Calithera Biosciences, Inc. (NASDAQ:CALA) rating on Friday, February 16. Citigroup has “Buy” rating and $14.0 target.
Investors sentiment decreased to 0.91 in 2018 Q1. Its down 1.29, from 2.2 in 2017Q4. It fall, as 16 investors sold Calithera Biosciences, Inc. shares while 29 reduced holdings. 10 funds opened positions while 31 raised stakes. 21.05 million shares or 12.94% less from 24.18 million shares in 2017Q4 were reported. Point72 Asia (Hong Kong) Ltd reported 0.01% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Gsa Cap Prns Ltd Liability Partnership accumulated 81,257 shares. 91,577 were reported by Secor Advisors Lp. Northern Tru Corporation owns 336,457 shares. Jennison Ltd holds 0% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 72,422 shares. Jpmorgan Chase has 6,167 shares. Savings Bank Of Mellon Corp reported 137,639 shares. Tiaa Cref Invest Mgmt Ltd holds 128,358 shares or 0% of its portfolio. Price T Rowe Md has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Services Automobile Association stated it has 55,633 shares or 0% of all its holdings. Grp Inc Inc has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Ubs Asset Mngmt Americas reported 0% stake. Deutsche Bankshares Ag has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 301,930 shares. Tudor Invest Et Al reported 32,360 shares stake. Manufacturers Life Insurance The, Ontario – Canada-based fund reported 24,905 shares.
More recent Calithera Biosciences, Inc. (NASDAQ:CALA) news were published by: Nasdaq.com which released: “Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June” on June 06, 2018. Also Nasdaq.com published the news titled: “Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National …” on May 16, 2018. Benzinga.com‘s news article titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018 was also an interesting one.
Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on August, 14. They expect $-0.33 EPS, down 120.00% or $0.18 from last year’s $-0.15 per share. After $-0.37 actual EPS reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts -10.81% EPS growth.